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methoxyamine is chosen by the Rapid Access to In-
tervention Development (RAID) program of the Na-
tional Cancer Institute as a potential new therapeutic
agent for further investigation [8].
To study the pharmacology and toxicology of
methoxyamine, an analytical method is desirable for
the measurement of methoxyamine in plasma sam-
ples. Since methoxyamine is a small organic amine,
it is very soluble in aqueous solution and plasma.
Moreover, methoxyamine possesses neither chro-
mophore for spectrophotometric detection nor enough
mass sensitivity for mass spectrometric detection. It
imposes a great difficulty for plasma sample prepa-
ration and detection. Although, it had been reported
that methoxyamine could be detected by polarogra-
phy [9], spectrophotometry [10], and HPLC–UV [11]
methods. Due to the lack of specificity, none of these
methods could be successfully applied to the mea-
surement of methoxyamine in plasma. An extensive
literature search revealed no publication in the field.
This paper describes the development and val-
idation of a tandem mass spectrometry method
for quantitative determination of methoxyamine in
plasma samples. Methoxyamine together with the
internal standard methoxyl-D3-amine was directly
derivatized in plasma sample with a novel chem-
ical agent 4-(N,N-diethylamino)benzaldehyde. The
product solution was injected into an on-line col-
umn for analyte extraction. After the elution of
extractives, the derivatized analytes were quanti-
tated by positive-electrospray-ionization tandem mass
spectrometry (ESI-MS-MS). The method developed
has been used to analyze methoxyamine in plasma
samples.
Experimental
Chemicals and solutions
Acetic acid, HPLC grade acetonitrile, 4-(N,N-di-
ethylamino)benzaldehyde, formic acid, and trifluoro-
acetic acid were from Aldrich. Methoxyamine hy-
drochloride (CH3ONH2.HCl) was from Sigma.
Methoxyl-D3-amine hydrochloride (CD3ONH2.HCl,
lot no. G582P1) was from CDN Isotopes Inc.
(Pointe-Claire, Que., Canada) and used as the internal
standard (I.S.).
A stock solution (10.0 mg/ml) of methoxyamine
hydrochloride (CH3ONH2.HCl) and a stock solution
(10.0 mg/ml) of methoxyl-D3-amine hydrochloride
(CD3ONH2.HCl) were prepared by dissolving appro-
priate amount of each compound in a known volume
of deionized water obtained from a NANOpure sys-
tem (Barnstead, Dubuque, IA, USA). A stock solution
(175 mg/ml) of 4-(N,N-diethylamino)benzaldehyde
was prepared by dissolving appropriate amount of the
compound in a known volume of aqueous solution
of acetic acid (H2O:CH3COOH, 1:1, v/v). The above
stock solutions were stored at 4 ◦C when not in use.
A working solution (5.00g/ml) of methoxyamine
(CH3ONH2) was prepared by a two-step dilution
(1/100, 8.88/100) of the methoxyamine hydrochloride
stock solution with deionized water. A working solu-
tion (60.0 ng/ml) of methoxyl-D3-amine (CD3ONH2)
was prepared by a three-step dilution (1/100, 1/100,
1.038/10) of the methoxyl-D3-amine hydrochloride
stock solution with deionized water. A working solu-
tion (10.0 mg/ml) of 4-(N,N-diethylamino)benzalde-
hyde was prepared by direct dilution of the stock
solution with an aqueous solution of formic acid
(H2O:HCOOH, 2:1, v/v).
Preparations of plasma calibrators
and controls
Pooled human plasma from voluntary blood donors
containing no detectable methoxyamine was obtained
from the Case Western Reserve University Hospital
and used as the blank plasma. Plasma methoxyamine
calibrators (1.00, 2.50, 5.00, 10.0, 25.0, 50.0, 125,
250, 500, 1000 ng/ml) were prepared by the serial di-
lution of 5.00g/ml methoxyamine working solution
with the blank human plasma. Plasma controls (5.00,
50.0, 500 ng/ml) were prepared by the serial dilution
of 5.00g/ml methoxylamine working solution with
the blank human plasma. All plasma samples were
placed on ice before the derivatization reaction, and
stored at −20 ◦C when not in use.
Derivatization of plasma methoxyamine
The derivatization reaction between the plasma
methoxyamine and 4-(N,N-diethylamino)benzalde-
hyde took place in a 0.65 ml Costar® microcentrifuge
tube (cat. no. 3208) from Corning Incorporated
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(Corning, NY, USA). Fifty microliters of H2O and
50.0l 60.0 ng/ml CD3ONH2 (internal standard)
were first added to 150l plasma sample contain-
ing CH3ONH2. After mixing, 50.0l 4-(N,N-diethyl-
amino)benzaldehyde solution (10.0 mg/ml) was added
to the mixture. The mixture was then vortexed, heated
at 80 ◦C for 1 h in a dry bath incubator (Fisher Sci-
entific, Pittsburgh, PA, USA), and centrifuged for
5 min in a C-1200 mini centrifuge (National Labnet
Co., Woodbridge, NJ, USA) before subjected to the
instrumental analysis.
Recovery studies
To assess the recovery of plasma methoxylamine
under different sample storage times and temperatures,
100 ng/ml methoxyamine plasma sample was prepared
by the dilution of methoxyamine working solution
(5.00g/ml) with the blank human plasma. Aliquots
of plasma sample (150l each) were pipetted into
Costar® microcentrifuge tubes and kept at 24, 4, and
−20 ◦C, respectively. At different time intervals, these
samples were processed and analyzed. The derivatiza-
tion of plasma methoxyamine was carried out at 24 ◦C
(i.e. room temperature) and 80 ◦C.
To validate the analytical procedures, plasma
methoxyamine standards and aqueous methoxyamine
references (5.00, 50.0, 500 ng/ml) were prepared sepa-
rately by the serial dilution of methoxyamine working
solution (5.00g/ml) with the blank human plasma
and deionized water. After the derivatization reaction
at 80 ◦C for 1 h, the samples were analyzed. The rel-
ative recovery of methoxyamine was determined by
comparing the mean-peak-area ratio of methoxyamine
to the internal standard in the plasma standards to the
mean-peak-area ratio of methoxyamine to the internal
standard in the aqueous references.
Pharmacokinetic study
Plasma methoxyamine elimination kinetics was
determined using male CD1 mice from the Jackson
Laboratory (Bar Harbor, ME, USA). The mice (four
mice per group) were randomly treated with single
bolus intraperitoneal injection of 2, 5 and 20 mg
methoxyamine hydrochloride (CH3ONH2.HCl)/kg
mouse. Blood samples were collected into heparinized
tubes at 1, 2.5, 5, 10, 20, 30, and 60 min after the
injection using a needle and syringe via an approach
to the heart under ether anesthesia. The blood sam-
ples were placed on ice and centrifuged within 2 h of
the collections. The resultant plasma samples were
stored at −20 ◦C prior to the analysis. In this work,
the pooled mouse plasma from mice without the in-
jection of methoxyamine hydrochloride was used as
the blank mouse plasma.
Instrumentation
The instrumentation system consisted of an HP1100
pump (Hewlett-Packard, Palo Alto, CA, USA), an
HP1100 autosampler, a stainless steel in-line filter
(0.5m pore, 0.23l dead volume, Upchurch Sci-
entific, Oak Harbor, WA, USA), an Oasis® HLB ex-
traction column (2.1 mm × 20 mm, Waters, Milford,
MA, USA), a Rheodyne 7000 two-position 6-port
switching valve (Supelco, Bellefonte, PA, USA), a
stainless steel splitting tee (1/16 in.×0.25 mm, Valco,
Houston, TX, USA), and a Quattro II triple quad-
rupole mass spectrometer (Micromass, Manchester,
UK).
The fluidic connection of the system is shown in
Fig. 1. High-pressure polyether ether ketone (PEEK)
tubing (0.0625 in. o.d.) was used. Except the connec-
tion between the splitting tee and the MS detector
(0.005 in. i.d.), all other connections used 0.01 in. i.d.
tubing. At the position 1 of the switching valve, the
extraction solvent carried the plasma sample from
the autosampler to the extraction column where the
analytes were retained and the plasma matrix was
excluded to the waste. At the position 2 of the switch-
ing valve, the elution solution eluted the retained
compounds from the extraction column, and carried
them to the splitting tee where the flow was diverted
to the ESI-MS-MS detector and the waste with a
split ratio of 1:5. The smaller flow (ca. 100l/min)
went to the MS detector and the larger one to the
waste.
On-line sample preparation
On-line extraction of methoxyamine and internal
standard from plasma were performed on an Oasis®
HLB extraction column. Prior to the analysis, the ex-
traction column was first equilibrated with the extrac-
tion solvent (H2O) at a flow rate of 2.0 ml/min for
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Fig. 1. The block diagram of the instrumentation system.
about 1.0 min with the switching valve on the posi-
tion 1 (Fig. 1). During the analyses, 10l derivatized
plasma sample was injected by the autosampler and
carried onto the extraction column by the extraction
solvent (H2O) at a flow rate of 2.0 ml/min. The plasma
matrix was washed away by the extraction solvent to
the waste, and the analytes of interest were extracted
by the column. At 1 min after the sample injection,
the switching valve was turned to the position 2. Si-
multaneously, the extraction solvent was switched to
the elution solution (95% acetonitrile + 5% H2O) at
a flow rate of 0.6 ml/min, which initiated the elution
of analytes from the extraction column. At 3 min af-
ter the elution, the switching valve was turned back to
the position 1. The column was continuously washed
with the elution solution at a flow rate of 2.0 ml/min
for another 0.5 min. Finally, the extraction column
was equilibrated with the extraction solvent at a flow
rate of 2.0 ml/min for 0.5 min before the next sample
injection. The total run time was about 5.0 min per
sample.
Mass spectrometric detection
The Quattro II triple quadrupole mass spectrometer
was operated under the positive-electrospray-ionization
mode (ESI+). It was tuned by infusion of a reaction
mixture of methoxyamine and methoxyl-D3-amine
(1.25g/ml each) with 4-(N,N-diethylamino)benzal-
dehyde (2.5 mg/ml) in 50% acetonitrile + 40%
H2O + 10% formic acid (which was needed for the
derivatization reaction) at a flow rate of 3l/min
with a syringe pump (Harvard Apparatus, South Nat-
ick, MA, USA). The optimized ionization conditions
were: nitrogen sheath and desolvation gas at 10 and
350 l/h, capillary at 3.5 kV, HV lens at 0.5 kV, cone at
34 V, skimmer at 1.5 V, RF lens at 0.2 V, ion source
temperature at 70 ◦C, ion energy at 1.2 V, low- and
high-mass resolution at 15, and mutliplier at 650 V.
Full-scan spectra were acquired in the continuum
mode at a scan rate 500 amu/s.
Multiple reaction monitoring (MRM) data were
acquired with the following parameters: m/z 207 >
149 for the derivatization product of methoxy-
lamine, m/z 210 > 149 for the derivatization prod-
uct of methoxyl-D3-amine, argon collision gas at
2.0–2.5bar, cone at 34 V, collision energy at 20 V for
each analyte, low- and high-mass resolution at 15 for
both quadrupole 1 and 3, dwell time at 0.3 s, and the
inter-scan delay at 0.03 s. The ionization parameters
were the same as those described previously.
Data analysis
Data acquisition and peak integration were done
with Micromass Masslynx software (Version 3.4). The
peak-area ratios of the derivatized methoxyamine to
the derivatized internal standard were plotted against
the methoxyamine concentration for the regression
equation. The plasma methoxyamine concentrations
of the unknown samples were determined by the re-
gression equation after obtaining the peak-area ratios
from their mass chromatograms.
Non-compartmental method was used to analyze
the data of pharmacokinetic study using WinNonLin
(Version 4.0.1) (Pharsight Corp., Mountain View, CA,
USA). The area under the curve (AUC) was deter-
mined by the linear trapezoidal rule, and the half-life
(T1/2) was estimated from the terminal portion of the
curve.
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Fig. 4. The mass spectra of the reactants and products of the derivatization reactions: (A) 1.25g/ml methoxyamine and methoxyl-D3-amine
in 50% acetonitrile+ 0.3% HCOOH; (B) 2.5 mg/ml 4-(N,N-diethylamino)benzaldehyde in 50% acetonitrile+ 10% formic acid and (C) the
1:1 mixture of (A) and (B) at the room temperature.
(Fig. 4A), 4-(N,N-diethylamino)benzaldehyde at m/z
178 (Fig. 4B), and the products of the derivatiza-
tion reactions at m/z 207 and 210 (Fig. 4C). The
positive ESI-MS-MS mode was used for both the
structure elucidation of the products of derivatiza-
tion reactions by selecting parent ions at m/z 207
and 210 and monitoring their daughter ions over
the m/z ratio of 100–230 (Fig. 5), and the quanti-
tative measurement of the derivatized analytes (m/z
207 > 149 for methoxyamine, and m/z 210 > 149
for methoxyl-D3-amine). Although many endoge-
nous compounds in plasma samples coeluted with
the derivatized analytes, the quantitative analysis by
ESI-MS-MS showed no interference to the deriva-
tized analytes. Therefore, it required no analytical
separation column.
Structure elucidation
It was clearly identified in Fig. 4 that there were
two quasi-molecular ions at m/z 207 and 210 in the re-
action mixture, which matched perfectly with the H+
adducts of the expected products of methoxyamine
(m/z 207) and methoxyl-D3-amine (m/z 210). Further-
more, the conversion efficiency of the derivatization
reaction could be revealed by the complete disappear-
ance of the mass peaks of methoxyamine (m/z 48) and
methoxyl-D3-amine (m/z 51).
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Fig. 5. The mass spectra of fragments ions from the products of the derivatization reactions. The daughter ions of peaks (m/z 210 and
207) in Fig. 4C.
To elucidate the structures of the products of the
derivatization reactions, the fragmentation of the
product peaks (m/z 207 and 210) was carried out
by colliding with argon gas in the collision cell in-
side of the mass spectrometer. The mass spectra of
daughter ions (fragments of the derivatized analytes)
were acquired by the ESI-MS-MS (Fig. 5). By the
comparison of the daughter ions spectra of the two
reaction products, the assignments of the fragment
ions could be made. Fig. 6 shows the assignments
of five major fragments of the expected products,
methoxyiminato-4-(N,N-diethylamino)benzaldehyde
and methoxyl-D3-iminato-4-(N,N-diethylamino)ben-
zaldehyde.
On-line sample preparation
Plasma sample preparation is often considered
as the bottleneck in drug analyses. To increase the
sample throughput, a Waters Oasis® HLB extraction
column (2.1 mm× 20 mm) was used for on-line sam-
ple preparation. According to its manufacturer, the
column was packed with a macroporous copolymer
of divinylbenzene and N-vinylpyrrolidone, which has
dual retention capability to both polar and non-polar
compounds. This type of column had been proven
to be effective for plasma sample preparations in
our previous works [15,16]. In this work, it was
found that the products of derivatization reaction,
methoxyiminato-4-(N,N -diethylamino)benzaldehyde
and methoxyl-D3-iminato-4-(N,N-diethylamino)ben-
zaldehyde retained strongly on the extraction column,
whereas the plasma proteins showed no sign of reten-
tion when H2O was used as the loading and washing
solvent. With the use of the in-line filter and the
after-use storage in 50% CH3CN aqueous solution,
the numbers of extraction performed by each column
were greater than 300 times.
The effect of flow rate of the sample extraction step
on the recovery of analytes was investigated. The data
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Fig. 6. The assignments of five major fragments of the derivatized
analytes, methoxyiminato-4-(N,N-diethylamino)benzaldehyde and
methoxyl-D3-iminato-4-(N,N-diethylamino)benzaldehyde.
indicated there was no significant change in the ana-
lyte recovery in the flow rate range of 0.5–3.0 ml/min.
Upon the consideration of sample throughput and col-
umn pressure, a flow rate of 2.0 ml/min was chosen in
the analytical procedures for sample extraction.
The elution of the derivatized analytes was largely
affected by the composition of mobile phase. It was
found that acetonitrile was a better organic solvent
than methanol in the terms of peak shape, retention
time, and signal response. The higher the percentage
of acetonitrile, the shorter was the retention time of the
derivatized analytes. In this work, an optimized com-
position of 95% CH3CN + 5% H2O was used as the
elution solution. It was worth noting that the addition
of volatile acid (i.e. formic acid, acetic acid, or trifluo-
roacetic acid) at the concentration ranged 0.05–4% to
the elution solution could cause dramatic reduction of
the analyte retention time due to the weakened inter-
action between the protonated analyte and the pack-
ing material in the extraction column, and resulted in
variations on the analyte recovery.
The flow rate of elution affects the analyte concen-
tration at the outlet of the extraction column. Since
ESI-MS is a concentration-dependent detector, the
flow rate of elution can affect peak shape and inten-
sity in a mass chromatogram. It was found that the
peak width became narrower with the increase of flow
rate (Fig. 7A). At the low flow rate, the peak height
was large at first. As the flow rate increased, the peak
height reached its maximum and declined dramati-
cally (Fig. 7B). In this work, an elution flow rate of
0.6 ml/min was chosen for the analytical procedures,
which provided the optimum detection sensitivity
and adequate elution time. At this flow rate, the ac-
tual fluid entering the mass spectrometer was about
100l/min after a 1:5 ratio of post-column splitting.
Specificity
Methoxyl-D3-amine, a deuterated methoxyamine,
was used as the internal standard for the measure-
ment of methoxyamine in plasma samples. Plasma
methoxyamine together with methoxyl-D3-amine
reacted with the derivatizing agent 4-(N,N-diethylam-
ino)benzaldehyde. The products of the derivatization
reaction, methoxyiminato-4-(N,N-diethylamino)ben-
zaldehyde and methoxyl-D3-iminato-4-(N,N-diethyl-
amino)benzaldehyde were detected by ESI-MS-MS.
The quantitation of plasma methoxyamine was carried
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Fig. 7. The effect of elution flow rate on the peak width and peak
height. The peak height was normalized by the peak height at
the flow rate of 1.00 ml/min. Plasma sample: the pooled human
plasma spiked with 100 ng/ml methoxyamine.
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Fig. 8. The representative mass chromatograms of human plasma samples: (A) the pooled human plasma without I.S. methoxyl-D3-amine;
(B) the pooled human plasma with I.S.; (C) 1.00 ng/ml plasma methoxyamine calibrator with I.S. and (D) 10.0 ng/ml plasma methoxyamine
calibrator with I.S.
out by monitoring one of the major fragments of
methoxyiminato-4-(N,N-diethylamino)benzaldehyde
(m/z 207> 149) together with that of methoxyl-D3-im-
inato-4-(N,N-diethylamino)benzaldehyde (m/z 210 >
149). The specificity of the analytical measurement
was shown in Fig. 8, which indicated no interference
from the plasma matrices.
Recovery
The relative recovery of the analytical method, de-
fined as the mean-peak-area ratio of methoxyamine
to internal standard in the plasma standard to the
mean-peak-area ratio of methoxyamine to internal
standard in the aqueous reference multiplies 100%,
was examined. By triplicate measurements, the mean
relative recoveries were 90.1, 91.4 and 94.7% at three
methoxyamine levels (5.00, 50.0 and 500 ng/ml).
Precision and accuracy
The precision and accuracy of the method were
determined by analyzing the plasma methoxyamine
controls at three concentration levels (5.00, 50.0 and
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Fig. 9. The representative mass chromatograms of mouse plasma samples: (A) the pooled mouse plasma with I.S.; (B) the plasma sample
collected 30 min after the injection with I.S. and (C) the plasma sample collected 2.5 min after the injection with I.S. Dosage: 2.00 mg
methoxyamine hydrochloride/kg mouse.
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500 ng/ml). Five and three replicates of each con-
centration were assayed for intra- and inter-assay
precision. The precision of the measurement of
methoxyamine in human plasma was shown in
Table 1. The coefficient of variations (CVs) for both
intra- and inter-assay were less than 4% at the three
concentration levels. The accuracy, defined as the
measured value divided by the accepted value multi-
plies 100%, were 95.0, 90.1, and 96.3% at the three
concentration levels by triplicate measurements.
Linearity
The linearity of the ESI-MS-MS response for
methoxyamine in human plasma was established over
the concentration range of 1.00–1000 ng/ml with a
correlation coefficient of 0.9999. The mean calibra-
tion curve from three separate calibration curves made
over one month of time gave a mean calibration equa-
tion y = 0.0579x with a CV of 2.4% for the slope.
Detection limits
The limit of detection (LOD) and the limit of quan-
tification (LOQ) for the method were calculated as 3
and 10 times of signal-to-noise ratio (peak-to-peak).
Based on five replicate analyses of 1.00 ng/ml plasma
methoxyamine calibrator, the calculated LOD and
LOQ of the method were 0.150 and 0.500 ng/ml,
respectively.
Pharmacokinetic study
The validated method was used to determine
plasma methoxyamine in mice with and without bolus
injections of methoxyamine hydrochloride. After the
frozen mouse plasma samples (−20 ◦C) were thawed
to the room temperature, 150l aliquots were used
for the analyses according to the procedures described
in Section 2, and the internal calibration curve was
Table 1
The intra- and inter-assay precision of plasma methoxyamine
Plasma
methoxyamine
(ng/ml)
Intra-assay
precision
(CV%, n = 5)
Inter-assay
precision
(CV%, n = 3)
5.00 2.2 3.7
50.0 1.3 1.1
500 1.9 0.49
plotted. The results demonstrated that mouse plasma
samples collected without injection of methoxyamine
hydrochloride showed no sign of interference from
endogeneous compounds, whereas plasma samples
following injections of methoxyamine hydrochloride
gave clear identification of methoxyamine. Represen-
tative mass chromatograms of mouse plasma samples
were given in Fig. 9. The plasma methoxyamine
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Fig. 10. The plasma methoxyamine concentration profiles in mice.
Dosages: (A) 2.00 mg methoxyamine hydrochloride/kg mouse; (B)
5.00 mg methoxyamine hydrochloride/kg mouse and (C) 20.0 mg
methoxyamine hydrochloride/kg mouse.
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Table 2
Pharmacokinetic parameters of methoxyamine
2 (mg/kg) 5 (mg/kg) 20 (mg/kg)
Tmax (min) 5.00 2.50 5.00
Cmax (ng/ml) 50.30 112.00 562.00
AUClast (min ng/ml) 704.82 2210.00 9535.25
T1/2 (min) 20.13 18.54 18.03
profiles from mice following single bolus intraperi-
toneal injections of 2, 5, and 20 mg methoxyamine
hydrochloride per kilogram of mouse were shown
in Fig. 10. The pharmacokinetic parameters of
methoxyamine were summarized in Table 2. The
results indicate the method developed may be used
to accurately determine methoxyamine in plasma
samples.
Conclusions
A ESI-MS-MS with on-line sample extraction
method for the quantitative determination of methoxy-
amine in human and mouse plasma has been deve-
loped and validated. Methoxyamine was accurately
determined in plasma through its reaction with 4-(N,N-
diethylamino)benzaldehyde under the acidic con-
ditions. The reaction product was confirmed by
fragmentation experiments. The protein-bound meth-
oxyamine was recovered by heating at 80 ◦C for 1 h.
This method was rugged and specific. It has been used
to analyze plasma samples from the pharmacokinetic
study in mice.
References
[1] M. Liuzzi, M. Talpeart-Borle, J. Biol. Chem. 260 (1985) 5252.
[2] S. Rosa, P. Fortini, M. Bignami, E. Dogliotti, Nucleic Acids
Res. 19 (1991) 5569.
[3] M. Liuzzi, M. Weinfeld, M.C. Paterson, Biochem. 26 (1987)
3315.
[4] S.L. Gerson, L. Liu, US Pat. Appl. Publ., US2002198264 A1
(2002).
[5] S.L. Gerson, L. Liu, PCT Int. Appl., WO 2001022199 A2
(2001).
[6] L. Liu, P. Taverna, C.M. Whitacre, S. Chatterjee, S.L. Gerson,
Clin. Cancer Res. 5 (1999) 2908.
[7] L. Liu, Y. Nakatsuru, S.L. Gerson, Clin. Cancer Res. 8 (2002)
2985.
[8] http://www.dtp.nci.nih.gov/docs/raid/raid index.html.
[9] P.E. Iversen, H. Lund, Anal. Chem. 41 (1969) 1322.
[10] T.K. Korpela, M.J. Makela, Anal. Biochem. 110 (1981) 251.
[11] E. Wang, E. Struble, P. Liu, A.P. Cheung, J. Pharm. Biomed.
Anal. 30 (2002) 415.
[12] V.A. Palm, Tables of Rate and Equilibrium Constants of
Heterolytic Organic Reactions, vol. 2 (1), Academy of
Sciences of the USSR, Moscow, 1976.
[13] M. Talpaert-Borle, M. Liuzzi, Biochim. Biophys. Acta 740
(1983) 410.
[14] J.C. Kotz, P.M. Treichel Jr., P.A. Harman, Chemistry and
Chemical Reactivity, fifth ed., Thomson, Toronto, 2003,
Chapter 16, p. 674.
[15] S. Yang, X. Zheng, Y. Xu, X. Zhou, J. Pharm. Biomed. Anal.
30 (2002) 781.
[16] Y. Xu, J.L. Grem, J. Chromatogr. B 783 (2003) 273.
Post-print standardized by MSL Academic Endeavors, the imprint of the Michael Schwartz Library at Cleveland State University, 
2017.
307
